News
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
The U.S. Food and Drug Administration (FDA) has issued a warning to patients and healthcare professionals regarding the use ...
16h
Newser on MSNMounjaro Beats Ozempic in Head-to-Head StudyMounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...
WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results